Skip to Main Content
Table 3

Relative quantitation of GD2 synthase mRNA of sequential samples in the BMs of stage 4 NB patients during the course of treatment and follow-upa

TimelinePatient
12345
At diagnosis 24.7 (0 m)b 21.0 (0 m) 107.1 (0 m) 4098.3 (0 m) 350.3 (0 m) 
During treatment 12.0 (6 m) 0 (6 m) 9.9 (6 m) 37.4 (6 m) 15.0 (1 m) 
Clinical remission 1.8 (12 m) 0 (12 m) 0 (12 m) 0 (13 m) 2.2 (10 m) 
Follow-up 4.2 (17 m) 0 (18 m) 0 (18 m) 50.8 (17 m) 8.5 (13 m) 
Follow-up 1.1 (24 m) 0 (31 m) 0 (24 m) 16.2 (24 m)  
Relapse    25.8 (30 m) 546.3 (18 m) 
Relapse    26.1 (41 m)  
Status PFc (73 m) PF (83 m) PF (100 m) Dead (50 m) Dead (22 m) 
TimelinePatient
12345
At diagnosis 24.7 (0 m)b 21.0 (0 m) 107.1 (0 m) 4098.3 (0 m) 350.3 (0 m) 
During treatment 12.0 (6 m) 0 (6 m) 9.9 (6 m) 37.4 (6 m) 15.0 (1 m) 
Clinical remission 1.8 (12 m) 0 (12 m) 0 (12 m) 0 (13 m) 2.2 (10 m) 
Follow-up 4.2 (17 m) 0 (18 m) 0 (18 m) 50.8 (17 m) 8.5 (13 m) 
Follow-up 1.1 (24 m) 0 (31 m) 0 (24 m) 16.2 (24 m)  
Relapse    25.8 (30 m) 546.3 (18 m) 
Relapse    26.1 (41 m)  
Status PFc (73 m) PF (83 m) PF (100 m) Dead (50 m) Dead (22 m) 
a

Relative quantitation was expressed as GD2 synthase/GAPDH with a detection threshold of 5.0, as described in “Patients and Methods.”

b

Months (m) after diagnosis.

c

PF, progression free.

Close Modal

or Create an Account

Close Modal
Close Modal